Blue Owl Capital Stock Rebounds Today, but Private-Credit Fears Still Hang Over OWL
13 March 2026

Blue Owl Capital Stock Rebounds Today, but Private-Credit Fears Still Hang Over OWL

NEW YORK, March 13, 2026, 11:52 EDT

Blue Owl Capital climbed roughly 2.2% to $8.80 during late-morning trading in New York on Friday. Shares of Ares advanced 4.6%, while Blackstone tacked on 4.1%. The moves signaled fresh momentum for alternative-asset managers.

Blue Owl has become something of a gauge for the private credit sector—the world of lending that bypasses banks. Investors are questioning if managers’ marks on private loans will stick in a softer market, particularly where portfolios lean on software deals and liquidity is getting squeezed.

The uncertainty intensified this week. After a look at software-induced volatility, JPMorgan cut values on certain loans linked to private-credit funds. Glendon Capital, referencing materials seen by the Financial Times and reported by Reuters on Thursday, accused Blue Owl and others of downplaying portfolio losses.

Morgan Stanley tightened withdrawal limits on a private-credit fund after redemption requests climbed to almost 11% of outstanding shares. The bank said the move was aimed at sidestepping asset sales in “periods of market dislocation.” 1330 & 101.5 WHBL

Investors aren’t hiding their doubts in listed funds. Publicly traded BDCs — business development companies offering retail access to private loans — are fetching just 78 cents per dollar of reported assets on average, Reuters said, quoting Morningstar. That’s a slide from 85 cents at the year’s open. Blue Owl Technology Finance stood out in Raymond James data released this week: trading at only 68 cents on the dollar.

Jack Shannon at Morningstar sees investors acting as if the sector’s “best days are behind it,” after years of quick expansion turned up the heat on competition. According to Evercore ISI’s Glenn Schorr, those discounts show just how much the market worries about recession risk and the prospect of more loan losses. Reuters

Blue Owl hasn’t stayed silent. According to Bloomberg, Co-President Craig Packer assured investors that those snapping up the firm’s $1.4 billion loan did so independently—no backroom deals, no extra perks, just standard due diligence.

The February sale remains a defining moment for the stock. Blue Owl moved $1.4 billion in loans out of three credit vehicles, aiming to return money to investors and bring down debt. At the time, Packer told analysts, “We’re not halting redemptions, we are simply changing the method by which we’re providing redemptions.” Blue Owl said the loans were sold at 99.7% of par—essentially full value. Reuters

One strong session hardly puts the debate to rest. Private credit has ballooned into a $2 trillion market, yet every fresh markdown, argument over asset values, or redemption limit chips away at investor faith in manager-reported numbers.

Blue Owl, headquartered in New York, oversaw upwards of $300 billion in assets at the end of December. Shares swung from $8.46 to $8.91 on Friday—buyers stepped in, though the action stayed measured.

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Constellation Energy

NASDAQ: CEG 95 / 100
#2 BUY

AerCap

NYSE: AER 93 / 100
#3 BUY

Walt Disney

NYSE: DIS 92 / 100
#4 ACCUMULATE

AIG

NYSE: AIG 90 / 100
#5 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Bank of America Stock Price Today: BAC Rises as Fed Capital Relief Meets Credit Fears
Previous Story

Bank of America Stock Price Today: BAC Rises as Fed Capital Relief Meets Credit Fears

ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus
Next Story

ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus